Herve Wallerand


Affiliation: CHU de Bordeaux
Country: France


  1. Wallerand H. [Intravesical chemotherapy and bladder cancer]. Prog Urol. 2009;19:868-71 pubmed publisher
    ..Superficial bladder cancer is treated by transuretral resection and in some cases by intravesical chemotherapy. Modalities, ways of administration and indications of these treatments will be presented and discussed. ..
  2. Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, Reiter R, et al. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol. 2010;28:473-9 pubmed publisher
    ..With the targeted therapy, oncology has entered into a new era, which is going to be critical in cancer treatment in combination with traditional anticancer drugs. ..
  3. Wallerand H, Cai Y, Wainberg Z, Garraway I, Lascombe I, Nicolle G, et al. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. Urol Oncol. 2010;28:180-8 pubmed publisher
    ..N/E- cadherin expression profile has a significant prognostic value in invasive BC. ..